In today’s briefing:
- Raffles Medical (RFMD SP): Stellar H1 Performance Driven by Resumption of Medical Tourism
- WuXi AppTec (603259.CH/2359.HK) 2022H1 – The Concerns Behind and the Outlook
Raffles Medical (RFMD SP): Stellar H1 Performance Driven by Resumption of Medical Tourism
- Raffles Medical (RFMD SP) reported strong H1 2022 results, with double-digit growth in revenue and net profit. With the resumption of international travel, the company is seeing increasing patients.
- While COVID-related revenue is declining, the company’s hospital business will benefit from the returning of foreign patients as well as resumption of elective surgeries for the domestic patients.
- Raffles Medical has received the approval to set up an IVF clinic in Hainan province of China.
WuXi AppTec (603259.CH/2359.HK) 2022H1 – The Concerns Behind and the Outlook
- It seems that Mr Market was not satisfactory with WuXi AppTec’s 2022H1 performance. If excluding COVID-19 projects (which are regarded as a one-time increment), the performance growth was not high.
- Considering that the CXO preliminary bid winning has declined largely in the US, domestic CXO would not begin to gradually reflect the slowdown of newly added orders until Q4.
- We are concerned about WuXi AppTec’s performance in 2023. As an old generation CXO, it’s hard to achieve V-shaped rebound. So, 2022 is a good time to offload the Company.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
